Broader data also indicate that anti-VEGF/VEGFR therapy combined with chemotherapy can improve progression-free survival and response rates in ovarian, breast, and prostate cancers, although with some increase in adverse events (19–21). This evidence concerns the gene VEGFA and prostate carcinoma.